These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 28862476

  • 21. Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma : Data of real-world utilization in Austria.
    Seeber A, Weiss L, Romeder F, Szkandera J, Kuehr T, Kostner S, Pichler P, Jaeger T, Kocher F, Greil R, Brodowicz T.
    Wien Klin Wochenschr; 2021 Jan; 133(1-2):21-25. PubMed ID: 31620878
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Olaratumab for the treatment of soft-tissue sarcoma.
    Pender A, Jones RL.
    Future Oncol; 2017 Oct; 13(24):2151-2157. PubMed ID: 28745071
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Olaratumab Approved for Soft-Tissue Sarcoma.
    Cancer Discov; 2016 Dec; 6(12):1297. PubMed ID: 27827816
    [Abstract] [Full Text] [Related]

  • 26. The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model.
    Higuchi T, Miyake K, Sugisawa N, Oshiro H, Zhang Z, Razmjooei S, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM.
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1075-1082. PubMed ID: 30929053
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A pilot study of first-line olaratumab, doxorubicin and ifosfamide in patients with metastatic soft tissue sarcoma.
    Vornicova O, Haim N, Bar-Sela G.
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):919-923. PubMed ID: 31410509
    [Abstract] [Full Text] [Related]

  • 29. Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas.
    Hammer KJ, Copeland VC, Loggers ET, Pollack SM, Wagner MJ, Cranmer LD.
    Am J Clin Oncol; 2020 Jun; 43(6):446-451. PubMed ID: 32235164
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma.
    Van Tine BA, Hirbe AC, Oppelt P, Frith AE, Rathore R, Mitchell JD, Wan F, Berry S, Landeau M, Heberton GA, Gorcsan J, Huntjens PR, Soyama Y, Vader JM, Alvarez-Cardona JA, Zhang KW, Lenihan DJ, Krone RJ.
    Clin Cancer Res; 2021 Jul 15; 27(14):3854-3860. PubMed ID: 33766818
    [Abstract] [Full Text] [Related]

  • 34. Economic evaluation of the GENESIS-SEFH report of olaratumab with doxorubicin in soft tissue sarcoma in advanced stages.
    Del Río-Valencia JC, Asensi-Díez R, Villalobos-Torres L, Clopés-Estela A, Fraga-Fuentes MªD.
    Farm Hosp; 2018 Sep 01; 42(5):204-211. PubMed ID: 30173639
    [Abstract] [Full Text] [Related]

  • 35. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.
    Chugh R, Griffith KA, Davis EJ, Thomas DG, Zavala JD, Metko G, Brockstein B, Undevia SD, Stadler WM, Schuetze SM.
    Ann Oncol; 2015 Jul 01; 26(7):1459-64. PubMed ID: 25858498
    [Abstract] [Full Text] [Related]

  • 36. Investigating a chimeric anti-mouse PDGFRα antibody as a radiosensitizer in primary mouse sarcomas.
    Song EJ, Ashcraft KA, Lowery CD, Mowery YM, Luo L, Ma Y, Campos LDS, Cardona DM, Stancato L, Kirsch DG.
    EBioMedicine; 2019 Feb 01; 40():224-230. PubMed ID: 30711517
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PC, dei Tos AP, van der Graaf WT, European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Lancet Oncol; 2014 Apr 01; 15(4):415-23. PubMed ID: 24618336
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.